Share
Save
Closed Loop and Education for Hypoglycemia Awareness Restoration
The purpose of the CLEAR study is to determine the effect on counterregulatory responses (CRR) of intervening (by attempting to strictly avoid hypoglycemia) to improve awareness of hypoglycemic symptoms among adults with type 1 diabetes (T1D) who have impaired awareness of hypoglycemia (IAH). IAH affects 20-25% of adults with T1D, and rises with increasing duration of T1D.
Study details:
Individuals with IAH exhibit blunted symptomatic and CR hormonal responses to hypoglycemia and, as such, have an impaired ability to respond to hypoglycemia. Thus, rates of severe hypoglycemia are up to 6-fold greater in those affected. Intensive management of T1D is necessary in preventing long-term complications, but can be complicated by recurrent episodes of hypoglycemia which lead to and sustain the CRR deficits of IAH.
Technologies such as continuous glucose monitoring (CGM) and hybrid closed-loop (HCL) systems can reduce severe hypoglycemia (and also may reduce IAH) but the ability of technology to reverse impaired CRR (as assessed with experimental hypoglycemia clamp) remains unclear. Behavioral and psycho-educational interventions targeting knowledge/skills gaps, as well as particular cognitions and behaviors driving recurrent hypoglycemia, can also reduce severe hypoglycemia and improve awareness. No studies have compared technology with such behavioral interventions in terms of assessing their impact on IAH or the CRR (as a primary outcome).
Unanswered questions include the degree of reduction in hypoglycemia required to restore awareness. Furthermore, participants may respond to different interventions according to their characteristics. For example, it remains unclear whether older individuals benefit from such interventions since they usually are excluded from studies.
Therefore, there is an urgent need to determine effective interventions that can reverse IAH in a large representative population of adults with T1D and IAH. The investigators propose to study the effect of specific interventions aimed at restoring. * the CRR (tested via an experimental hypoglycemia clamp procedure).
* hypoglycemia awareness (self-reported via the Towler Questionnaire during the experimental hypoglycemia clamp procedure). The study will use a Sequential Multiple Assignment Randomized Trial (SMART) design. At baseline, all participants who are HCL naïve will be randomized to HCL or Usual Care (UC) plus brief education (My HypoCOMPaSS) with a follow-up of two years.
UC will consist of real-time continuous glucose monitoring (CGM) and insulin delivery via pump or multiple daily injections. Participants who fail to increase their CRR at 12 months will be randomized, or assigned, to a second intervention consisting of a small-group educational program focusing on motivations and unhelpful cognitions acting as barriers to hypoglycemia avoidance (HARPdoc). At baseline, all participants who are HCL non-naïve will be randomized to optimized HCL or HCL plus My HypoCOMPaSS; those with non-responsive CRR at 12 months will be randomized to either continue HCL (on the basis they need a longer period to reverse impaired CRR and total symptomatic responses) or to the HARPdoc intervention.
Participants randomized to an HCL device are expected to wear the device continually, as well as a CGM. The My HypoCOMPaSS education requires 4-5 hours of training, whereas, the HARPdoc education requires four training sessions of seven hours each during weeks 1,2,3, and 6. The specific aims and hypotheses are as follows:.
Aim 1: To determine the effect on CRR (epinephrine increase ≥ 125 pg/ml over baseline) and total symptom responses (Towler Questionnaire increase ≥ 20% over baseline) during a hyperinsulinemic-hypoglycemic clamp procedure (glucose \< 50 mg/dl) after 12 months of HCL versus Usual Care plus My HypoCOMPaSS Educational Intervention among adults with T1D and IAH who have never used HCL therapy previously. Hypothesis 1: At 12 months, those allocated to Usual Care plus My HypoCOMPaSS will be more likely to have improved CRR and total symptomatic responses than those allocated to HCL. Aim 2: To determine the effect on CRR and total symptom responses at 12 months of HCL plus My HypoCOMPaSS versus HCL alone among adults with T1D and IAH who are currently using HCL therapy prior to entering the study.
Hypothesis 2: At 12 months, those allocated to HCL plus My HypoCOMPaSS will be more likely to have improved hypoglycemic awareness and improved CRR than those using HCL alone. Aim 3: To determine the durability of effect over 24 months of the intervention that improves CRR at 12 months among adults with type 1 diabetes and IAH at baseline. Hypothesis 3: At 24 months, CRR will improve further among those who had restored CRR at 12 months.
Aim 4. To determine the effect on hypoglycemic awareness (Towler Questionnaire increase ≥ 20% over baseline) and CRR (epinephrine increase ≥ 125 pg/ml over baseline) during a hyperinsulinemic hypoglycemic clamp procedure at 24 months of an in-depth educational program (HARPdoc), initiated throughout months 12-24, among adults with T1D and IAH at baseline, for whom the intervention allocated at baseline did not restore CRR at 12 months. Hypothesis 4: At 24 months, those allocated to HARPdoc for months 12-24 months will be more likely to have improved hypoglycemic awareness and CRR than those who continue with the therapy allocated at baseline.
Eligibility criteria
Researchers look for people who fit a certain description, called eligibility criteria. See if you qualify.
Inclusion criteria
Exclusion criteria
Eligibility
Age eligible for study : 18 and older
Healthy volunteers accepted : No
Gender eligible for study: All
Things to know
Study dates
Study start: 2025-01-01
Primary completion: 2027-06-30
Study completion finish: 2027-12-31
Study type
TREATMENT
Phase
NA
Trial ID
NCT06325202
Intervention or treatment
DEVICE: Omnipod 5 or Medtronic 780G
BEHAVIORAL: My HypoCOMPaSS Education
BEHAVIORAL: HARPdoc Education
Conditions
- • Diabetes Mellitus, Type 1
Find a site
Closest Location:
University of Melbourne
Research sites nearby
Select from list below to view details:
University of Melbourne
Fitzroy, Victoria, Australia
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
| Participant Group/Arm | Intervention/Treatment |
|---|---|
EXPERIMENTAL: current HCL non-user: HCL x 24 months
| DEVICE: Omnipod 5 or Medtronic 780G
|
EXPERIMENTAL: current HCL non-user: HCL x 12 months, then HCL x an additional 12 months
| DEVICE: Omnipod 5 or Medtronic 780G
|
EXPERIMENTAL: current HCL non-user: HCL x 12 months, then HCL + HARPdoc x 12 months
| DEVICE: Omnipod 5 or Medtronic 780G
|
ACTIVE_COMPARATOR: current HCL non-user: Usual Care and My HypoCOMPaSS x 12 months, then HCL x 12 months
| DEVICE: Omnipod 5 or Medtronic 780G
|
ACTIVE_COMPARATOR: current HCL non-user: Usual Care and My HypoCOMPaSS x 24 months
| BEHAVIORAL: My HypoCOMPaSS Education
|
EXPERIMENTAL: current HCL user: HCL x 24 months
| DEVICE: Omnipod 5 or Medtronic 780G
|
EXPERIMENTAL: current HCL user: HCL x 12 months, then HCL x an additional 12 months
| DEVICE: Omnipod 5 or Medtronic 780G
|
EXPERIMENTAL: current HCL user: HCL x 12 months, then HCL + HARPdoc x 12 months
| DEVICE: Omnipod 5 or Medtronic 780G
|
ACTIVE_COMPARATOR: current HCL user: HCL and My HypoCOMPaSS x 12 months, then HCL x 12 months
| DEVICE: Omnipod 5 or Medtronic 780G
|
ACTIVE_COMPARATOR: current HCL user: HCL + My HypoCOMPaSS x 12 months, then HCL + My HypoCOMPaSS + HARPDOC x 12 months
| DEVICE: Omnipod 5 or Medtronic 780G
|
EXPERIMENTAL: current HCL user: HCL + My HypoCOMPaSS x 24 months
| DEVICE: Omnipod 5 or Medtronic 780G
|
What is the study measuring?
Primary outcome
| Primary Outcome Measure | Primary Outcome Description | Primary Outcome Time Frame |
|---|---|---|
| epinephrine (pg/ml) | a change in epinephrine (pg/ml) that exceeds 125 pg/ml between (1) 12 months and baseline, and (2) 24 months and baseline | measured during the clamp studies at 0 (baseline), 12, and 24 months |
| Towler questionnaire | the Towler questionnaire consists of 12 questions each on a 0-6 Likert scale; a change in the questionnaire that exceeds 20% between (1) 12 months and baseline, and (2) 24 months and baseline | measured during the clamp studies at 0 (baseline), 12, and 24 months |
Secondary outcome
| Secondary Outcome Measure | Secondary Outcome Description | Secondary Outcome Time Frame |
|---|---|---|
| geometric mean of plasma glucagon | geometric mean of plasma glucagon | measured during the clamp studies at 0 (baseline), 12, and 24 months |
| geometric mean of plasma pancreatic polypeptide | geometric mean of plasma pancreatic polypeptide | measured during the clamp studies at 0 (baseline), 12, and 24 months |
| geometric mean of plasma free fatty acids | geometric mean of plasma free fatty acids | measured during the clamp studies at 0 (baseline), 12, and 24 months |
| glucose infusion rate | glucose infusion rate | measured during the clamp studies at 0 (baseline), 12, and 24 months |
| HbA1c | glycated hemoglobin | measured during the clamp studies at 0 (baseline), 12, and 24 months |
| % of time with sensor hypoglycemia <70 mg/dL | % of time with hypoglycemia \<70 mg/dL determined from the continuous glucose monitor (CGM) sensor | measured during the four weeks prior to each clamp study at 0 (baseline), 12, and 24 months |
| % of time with sensor hypoglycemia <54 mg/dL | % of time with hypoglycemia \<54 mg/dL determined from the continuous glucose monitor (CGM) sensor | measured during the four weeks prior to each clamp study at 0 (baseline), 12, and 24 months |
| number of hypoglycemia events | number of hypoglycemia events determined from the continuous glucose monitor (CGM) sensor | measured during the four weeks prior to each clamp study at 0 (baseline), 12, and 24 months |
| % time with sensor glucose in range | % time with glucose in range determined from the continuous glucose monitor (CGM) sensor | measured during the four weeks prior to each clamp study at 0 (baseline), 12, and 24 months |
| sensor glucose coefficient of variation | sensor glucose coefficient of variation determined from the continuous glucose monitor (CGM) sensor | measured during the four weeks prior to each clamp study at 0 (baseline), 12, and 24 months |
| sensor use as the average numbers of days per week | sensor use as the average number of days per week determined from the continuous glucose monitor (CGM) sensor | measured during the four weeks prior to each clamp study at 0 (baseline), 12, and 24 months |
| glycemia risk index | glycemia risk index determined from the continuous glucose monitor (CGM) sensor | measured during the four weeks prior to each clamp study at 0 (baseline), 12, and 24 months |
| Trail Making Test - Part B | amount of time required to complete the Trail Making Test - Part B | measured during the clamp studies at 0 (baseline), 12, and 24 months |
| Four Choice Reaction Time | Four Choice Reaction Time, which measures reaction time and motor coordination | measured during the clamp studies at 0 (baseline), 12, and 24 months |
| sleep duration | sleep duration determined from an activity monitor smartwatch | measured during the two weeks prior to each clamp study at 0 (baseline), 12, and 24 months |
| sleep quality | sleep quality determined by an activity monitor smartwatch | measured during the two weeks prior to each clamp study at 0 (baseline), 12, and 24 months |
| 24-hour step count | 24-hour step count determined by an activity monitor smartwatch | measured during the two weeks prior to each clamp study at 0 (baseline), 12, and 24 months |
| exercise bouts | exercise bouts determined by an activity monitor smartwatch | measured during the two weeks prior to each clamp study at 0 (baseline), 12, and 24 months |
| resting heart rate | resting heart rate determined by an activity monitor smartwatch | measured during the two weeks prior to each clamp study at 0 (baseline), 12, and 24 months |
| heart rate during exercise | heart rate during exercise determined by an activity monitor smartwatch | measured during the two weeks prior to each clamp study at 0 (baseline), 12, and 24 months |
| heart rate variability | heart rate variability determined by an activity monitor smartwatch | measured during the two weeks prior to each clamp study at 0 (baseline), 12, and 24 months |
| Hypo-METRICS questionnaire | Hypo-METRICS questionnaire, a Person-Reported Outcome Measure (PROM) specific to hypoglycemia | measured two weeks prior to each clamp study at 0 (baseline), 12, and 24 months |
| Hypoglycemic Confidence Scale | Hypoglycemic Confidence Scale, a Person-Reported Outcome Measure (PROM) specific to hypoglycemia, the range is 0 through 27 and higher scores correspond to higher confidence | measured two weeks prior to each clamp study at 0 (baseline), 12, and 24 months |
| Hypoglycemia Fear Survey-II | Hypoglycemia Fear Survey-II, a Person-Reported Outcome Measure (PROM) specific to hypoglycemia | measured two weeks prior to each clamp study at 0 (baseline), 12, and 24 months |
| Attitudes to Awareness of Hypoglycaemia | Attitudes to Awareness of Hypoglycaemia, a Person-Reported Outcome Measure (PROM) specific to hypoglycemia | measured two weeks prior to each clamp study at 0 (baseline), 12, and 24 months |
| Type 1 Diabetes Distress Scale | Type 1 Diabetes Distress Scale, a Person-Reported Outcome Measure (PROM) specific to hypoglycemia | measured two weeks prior to each clamp study at 0 (baseline), 12, and 24 months |
| Diabetes Self-Management Questionnaire | Diabetes Self-Management Questionnaire, a Person-Reported Outcome Measure (PROM) specific to hypoglycemia | measured two weeks prior to each clamp study at 0 (baseline), 12, and 24 months |
| Diabetes Management Experiences Questionnaire | Diabetes Management Experiences Questionnaire, a Person-Reported Outcome Measure (PROM) specific to hypoglycemia | measured two weeks prior to each clamp study at 0 (baseline), 12, and 24 months |
| PROMIS Sleep Disturbance - Short Form 8a | PROMIS Sleep Disturbance - Short Form 8a | measured two weeks prior to each clamp study at 0 (baseline), 12, and 24 months |
| Hospital Anxiety and Depression Scale | Hospital Anxiety and Depression Scale | measured two weeks prior to each clamp study at 0 (baseline), 12, and 24 months, the range is 0 through 42 and higher scores correspond to higher anxiety and depression |
| 12-Item Hypoglycemia Impact Profile | 12-Item Hypoglycemia Impact Profile, a Person-Reported Outcome Measure (PROM) specific to hypoglycemia | measured two weeks prior to each clamp study at 0 (baseline), 12, and 24 months |
| EQ-5D-5L | EQ-5D-5L, a quality-of-life scale with 5 dimensions | measured two weeks prior to each clamp study at 0 (baseline), 12, and 24 months |
| device-related adverse events | device-related adverse events | throughout the duration of the 24 months of follow-up |
| severe hypoglycemic events, self-reported on a CLEAR data collection form | severe hypoglycemic events, self-reported on a CLEAR data collection form | throughout the duration of the 24 months of follow-up |
| diabetic ketoacidosis (DKA) events | diabetic ketoacidosis (DKA) events | throughout the duration of the 24 months of follow-up |
| number of participants with hospitalizations | number of participants with hospitalizations | throughout the duration of the 24 months of follow-up |
| number of participants with emergency room (ER) visits | number of participants with emergency room (ER) visits | throughout the duration of the 24 months of follow-up |
| major adverse cardiovascular events (MACE) | major adverse cardiovascular events (MACE) | throughout the duration of the 24 months of follow-up |
| all-cause mortality | all-cause mortality | throughout the duration of the 24 months of follow-up |
Frequently Asked Questions
Please note: some questions and answers are submitted by anonymous patients or using AI, and have not been verified by Clinrol
No questions submitted. Be the first to ask a question!